# EDGAR Filing Document

**Accession Number:** 0000072444
**File Stem:** 0001213900-26-072359
**Filing Date:** 2026-6
**Character Count:** 9968
**Document Hash:** a241df5cc01762732f7b7a7cae18f8d2
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-072359.hdr.sgml**: 20260626

**ACCESSION NUMBER**: 0001213900-26-072359

**CONFORMED SUBMISSION TYPE**: DEFA14A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260626

**DATE AS OF CHANGE**: 20260626

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Vaxart, Inc.
- **CENTRAL INDEX KEY:** 0000072444
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 591212264
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** DEFA14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35285
- **FILM NUMBER:** 261124037

**BUSINESS ADDRESS:**
- **STREET 1:** 310 UTAH AVENUE, SUITE 150
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **BUSINESS PHONE:** (650) 550-3500

**MAIL ADDRESS:**
- **STREET 1:** 310 UTAH AVENUE, SUITE 150
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Aviragen Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20160413

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Biota Pharmaceuticals, Inc.
- **DATE OF NAME CHANGE:** 20121113

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NABI BIOPHARMACEUTICALS
- **DATE OF NAME CHANGE:** 20100719

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE 14A INFORMATION**

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Filed by the Registrant ☒ <br> Filed by a Party other than the Registrant ☐

Check the appropriate box:

☐ Preliminary Proxy Statement

☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

☐ Definitive Proxy Statement

☒ Definitive Additional Materials

☐ Soliciting Material Pursuant to § 240.14a-12

**VAXART, INC.**

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement if Other Than the Registrant)

Payment of Filing Fee (Check the appropriate box)

☒ No fee required. <br> ☐ Fee paid previously with preliminary materials <br> ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

**Vaxart Publishes Presentation Urging Shareholders to Vote "FOR" ALL Six of the Company's Highly**

**Qualified Director Nominees on the WHITE Proxy Card TODAY**

*Details Strategic Actions Taken by the Board to Advance the Company's Pipeline and Drive Value Creation*

 

*Vaxart's Purpose-Built Board Brings the Proven Expertise Needed to Oversee its Next Phase of Growth*

 

*Dissident Nominees Lack Relevant Clinical-Stage Biotech Expertise, Misrepresented Their Qualifications* 

*and Offered No Credible Ideas for Value Creation*

 

*Vaxart Has Made Multiple Settlement Offers to the Dissident Shareholder Group – Daniel Houle Insists on* 

*Making This Proxy Contest About Winning a Seat for Himself*

 

*Visit Vote.Vaxart.com for Additional Information and Voting Resources* 

**SOUTH SAN FRANCISCO, Calif., June 26, 2026** — Vaxart, Inc. (OTCQX: VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, today published a presentation urging shareholders to vote **"FOR" ALL** six of the Company's highly qualified director nominees on the **WHITE** proxy card in connection with its upcoming Annual Meeting of Stockholders scheduled to be held on July 16, 2026.

Highlights of the presentation include:

**<u>Strategic Execution at a Pivotal Moment</u>**

● **Vaxart is developing game-changing oral vaccines with the potential to redefine vaccine delivery and immune responses:** 

○ Vaxart is advancing multiple vaccine programs across high-value markets, including COVID-19, norovirus and influenza.

○ Management is pursuing a disciplined development strategy that prioritizes programs with the strongest scientific rationale, commercial opportunity and funding pathways.

○ Through its Phase 2b COVID-19 trial, Vaxart is working toward topline 12-month safety and immunogenicity data from the approximately 400-participant Sentinel Cohort.

○ Vaxart is also targeting a full efficacy and safety readout from its approximately 5,100-participant Main Cohort, representing a significant clinical and value-creation milestone.

● **Vaxart's Board has taken prudent steps to enable Vaxart to continue advancing its programs in a challenging environment:** 

○ Vaxart has been executing through immense industry pressures brought upon by significant regulatory, funding and policy disruption, including two BARDA stop-work orders that impacted Vaxart and many other vaccine companies.

○ Through CEO Steven Lo's leadership and negotiations with government stakeholders, the Company secured the continuation of BARDA funding for its lead COVID-19 program.

○ Vaxart entered into a $25 million share purchase agreement, providing flexible access to capital, if needed, to support continued execution toward key milestones.

○ The Board's decision to raise $40 million in 2025 extended the Company's runway, enabling it to enter key partnerships and advance its programs.

**<u>The Right Board to Oversee the Path Forward</u>**

● **The Board is purpose-built to guide Vaxart through its next phase of value creation.** 

○ The Board is aligned with the Company's evolving strategic priorities, with substantial expertise across biotech, vaccine development, clinical trials and regulatory affairs.

○ The Board's experience has helped secure continued BARDA funding, establish the Dynavax partnership and enable additional financing flexibility through the Lincoln Park Capital agreement.

○ Mr. Lo, Dr. Elaine J. Heron and Dr. David Wheadon are instrumental to Vaxart's success and have the judgment, credibility and relationships needed to oversee the Company's most important future opportunities.

● **The Board is responsive to shareholder feedback and acts in shareholders' best interests:** 

○ The Board has added two new independent directors — Dr. James B. Breitmeyer and Kevin Finney — over the last 18 months as part of its ongoing refreshment efforts, resulting in an average director tenure of approximately 2.3 years.

○ In 2025, the Board further strengthened independent oversight through the appointment of W. Mark Watson as Lead Independent Director.

○ The Board maintains an active dialogue with shareholders and withdrew its reverse split proposal for this upcoming Annual Meeting following feedback.

**<u>The Dissident Campaign is Risking Vaxart's Momentum</u>**

● **Replacing <u>ANY</u> of Vaxart's highly qualified directors with the dissident nominees is not in shareholders' best interests:** 

○ None of the dissident nominees has experience leading a public clinical-stage biotech company or with vaccine development, regulatory affairs and clinical trial oversight.

○ The dissident nominees have drastically exaggerated their qualifications, and Daniel Houle's reckless public statements show that he should not serve on Vaxart's Board.

○ Collectively, they present unacceptable risk for a company approaching critical inflection points like Vaxart.

● **Vaxart has made good-faith efforts to resolve the proxy contest:** 

○ Vaxart has made multiple settlement offers to the dissident shareholder group in an effort to resolve the proxy contest.

○ The Board's proposals are highly reasonable and reflect what it has heard other independent shareholders want to see.

○ Mr. Houle is waging a self-interested campaign primarily focused on "winning" a Board seat for himself rather than reaching a constructive resolution that would benefit all Vaxart shareholders.

**Vote "FOR" ALL 6 of Vaxart's highly qualified director nominees on the WHITE proxy card TODAY!**

If you have questions or require assistance with voting your shares, please call Vaxart's proxy solicitor:

Campaign Management, LLC

**Toll-Free: +1 (855) 264-1527**

Additional shareholder resources and voting information can be found at Vote.Vaxart.com.

**About Vaxart** 

Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the Company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart's development programs currently include pill vaccines designed to protect against coronavirus, norovirus, and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart's first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.

**Cautionary Language Concerning Forward-Looking Statements** 

**Important Additional Information and Where to Find It**

Vaxart has filed a definitive proxy statement and form of white proxy card with the U.S. Securities and Exchange Commission (the "SEC") in connection with its solicitation of proxies for the 2026 Annual Meeting of Stockholders (the "Annual Meeting"). Stockholders are able to obtain the Company's proxy statement, any amendments or supplements to the proxy statement and other documents filed by the Company with the SEC at no charge at the SEC's website at www.sec.gov. Copies are also available at no charge at the Company's website at https://investors.vaxart.com/financials-filings/sec-filings.

**Investor Contact**

Michael Fein

Campaign Management

(855) 264-1527

**Media Contact**

Aaron Palash / Adam Pollack

Joele Frank, Wilkinson Brimmer Katcher

(212) 355-4449